Furthermore, the inhibition of PDE5 increases cGMP levels in a concentration-dependent manner, producing anti-proliferative and pro-apoptotic effects in PASMCs from patients with PAH. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.